Bristol Myers Squibb Chief Medical Officer Cristian Massacesi, M.D., has told Fierce that the latest data for its ...

AstraZeneca executives were adamant that detailed data from a phase 3 study of the pharma’s next-generation antibody-drug ...

The Big Pharma has already launched a phase 2 trial of JNJ-6143 at a 50 mg daily dose in around 100 patients with metastatic androgen pathway modulation-resistant prostate cancer (mAPMR), an advanced ...

Roche has shed more light on its investigational KRAS G12C inhibitor's phase 3 victory over Amgen’s Lumakras and Bristol Myers Squibb’s Krazati. | Roche has shed more light on its investigational KRAS ...

Despite the sweeping scope of the ban covering various types of drug molecules, biopharma business development teams can ...

Gilead has struck a deal to acquire PepStar Therapeutics’ oral IL-23 receptor inhibitor program for $1.275 billion, positioning itself as a would-be challenger to Johnson & Johnson’s Icotyde across a ...

Merck & Co. and Moderna always knew they would be making headlines in Madrid this week—just not in the way it panned out. | Merck & Co. and Moderna always knew they would be making headlines in Madrid ...

Merck & Co. and Moderna have shared highly anticipated phase 3 data on their cancer vaccine, revealing a primary endpoint hit ...

Lycia Therapeutics is banking on a $227.8 million IPO as the biotech seeks to finance its pipeline of protein degraders for ...

AbbVie’s next-generation Crohn’s disease combination candidate has beaten Skyrizi in a midphase clinical trial. Skyrizi is a ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Takeda has lifted the lid on the phase 3 win for its next-generation claudin18.2 drug, with the antibody-drug conjugate (ADC) demonstrating overall survival (OS) of 10.2 months in tough to treat ...